Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president with responsibility for commercialisation of medicines from Lundbeck's partnership with Japanese pharmaceutical firm Otsuka.
Eggert joined Lundbeck in 2010 and since then has driven marketing strategy development and execution and the collaboration between business areas and stakeholders. In this role, Eggert strengthened and developed Lundbeck's strategic marketing at a time when the Danish pharmaceutical firm is poised to launch several medicines, including the antidepressant vortioxetine; Selincro for the treatment of alcohol dependence; and the once-monthly formulation of aripiprazole for the treatment of schizophrenia.
Abel has been appointed as vice president with responsibility for commercialisation of medicines from Lundbeck's partnership with Otsuka. The two firms entered a broad-reaching partnership in the areas of psychiatry and neurology in November 2011, and are collaborating on the development of up to five innovative medicines for the treatment of various brain disorders.
Klaus Abel
Abel will specifically focus on collaborative development and commercialisation of two medicines: the once-monthly aripiprazole formulation for the treatment of schizophrenia, and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.
Abel has worked for Lundbeck since 2000 and has held positions in a variety of different areas, including leading roles in Lundbeck's business development department, managing director of Lundbeck's affiliate in Australia and New Zealand, and most recently executive director with commercial responsibility for established Lundbeck products such as Cipralex, Ebixa and Azilect.